Phase 3 single-arm Hizentra study in adults with secondary immune deficiency after B-cell targeting CAR T-cell or T-cell redirecting therapy

Phase 3, open-label, single-arm trial of polyvalent human immunoglobulin in secondary immunodeficiency (SID), sponsored by CSL Behring. Primary endpoint: Number of serious bacterial infections per participant. Planned start Oct 2026; status: authorised.